The role of extracelluar matrix in osteosarcoma progression and metastasis.

The role of extracelluar matrix in osteosarcoma progression and metastasis.
复制标题

DOI:
10.1186/s13046-020-01685-w
复制
发表时间:
2020-09-04
期刊:
Journal of experimental & clinical cancer research : CR
影响因子:
--
通讯作者:
Duan Z
Duan Z
中科院分区:
其他
文献类型:
--
作者:
Cui J;Dean D;Hornicek FJ;Chen Z;Duan Z

文献摘要

参考文献

被引文献

相似文献

骨肉瘤(OS)是最常见的原发性骨恶性肿瘤,由于其高的肺转移率,导致相当高的发病率和死亡率。虽然新辅助化疗使局部OS患者的5年生存率从20%提高到65%以上,但转移患者的结局仍然令人沮丧。此外,在过去的四十年中,治疗方案没有显著改善患者的结局,并且转移仍然是死亡和治愈性治疗障碍的主要原因。这些护理方面的局限性引起了许多工作,重点是OS发病机制和新靶点,包括肿瘤生态位因子。OS以其标志性的丰富的类骨质细胞外基质(ECM)的产生而闻名,这超出了简单的生理生长支持。ECM的异常信号传导和结构成分是OS发育的丰富启动子,并且最近的工作显示了由这些大分子诱导的特异性致病表型。在这里,我们总结了目前的发展概述了ECM如何有助于OS进展和转移的支持机制。我们还说明了潜在的致瘤性ECM元素作为预后生物标志物和治疗靶点在不断发展的临床管理OS。
Osteosarcoma (OS) is the most common primary bone malignancy and responsible for considerable morbidity and mortality due to its high rates of pulmonary metastasis. Although neoadjuvant chemotherapy has improved 5-year survival rates for patients with localized OS from 20% to over 65%, outcomes for those with metastasis remain dismal. In addition, therapeutic regimens have not significantly improved patient outcomes over the past four decades, and metastases remains a primary cause of death and obstacle in curative therapy. These limitations in care have given rise to numerous works focused on mechanisms and novel targets of OS pathogenesis, including tumor niche factors. OS is notable for its hallmark production of rich extracellular matrix (ECM) of osteoid that goes beyond simple physiological growth support. The aberrant signaling and structural components of the ECM are rich promoters of OS development, and very recent works have shown the specific pathogenic phenotypes induced by these macromolecules. Here we summarize the current developments outlining how the ECM contributes to OS progression and metastasis with supporting mechanisms. We also illustrate the potential of tumorigenic ECM elements as prognostic biomarkers and therapeutic targets in the evolving clinical management of OS.
DOI: 10.3892/mmr.2016.5663
发表时间: 2016-10
影响因子: 3.4
作者:
Cheng G;Gao F;Sun X;Bi H;Zhu Y
通讯作者: Zhu Y
DOI: 10.1042/cs20050286
发表时间: 2006-06-01
期刊: CLINICAL SCIENCE
影响因子: 6
作者:
Felx, Melanie;Guyot, Marie-Claude;Moldovan, Florina
通讯作者: Moldovan, Florina
DOI: 10.1016/j.yexcr.2017.08.035
发表时间: 2017-11-15
影响因子: 3.7
作者:
Chaddad, Hassan;Kuchler-Bopp, Sabine;Idoux-Gillet, Ysia
通讯作者: Idoux-Gillet, Ysia
DOI: 10.1126/science.1171643
发表时间: 2009-06-26
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Discher DE;Mooney DJ;Zandstra PW
通讯作者: Zandstra PW
DOI: 10.1242/jcs.073346
发表时间: 2010-11-15
影响因子: 4
作者:
Cseh, Botond;Fernandez-Sauze, Samantha;Van Obberghen-Schilling, Ellen
通讯作者: Van Obberghen-Schilling, Ellen